Trial · NCT04950075
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075, Phase 2, Active not recruiting, Inhibrx Biosciences, Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of INBRX-109 in Conventional Chondrosarcoma. Trials, record NCT04950075. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04950075
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of INBRX-109 in Conventional Chondrosarcoma
- NCT number
- NCT04950075
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 206 participants, actual
- Lead sponsor
- Inhibrx Biosciences, Inc
- Conditions
- Conventional Chondrosarcoma
- Interventions
- INBRX-109, Placebo
- First posted
- 2021-07-06
- Last updated
- 2026-07-14
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival per RECISTv1.1 by real time IRR comparing INBRX-109 and placebo | 3 years | Progression-free survival per RECISTv1.1 will be determined. |
| Secondary | Overall survival of patients comparing INBRX-109 and placebo | 3 years | Overall Survival in the ITT population |
| Secondary | ORR per RECISTv1.1 by real-time IRR. | 3 years | Tumor response will be determined by RECISTv1.1. |
| Secondary | PFS per RECISTv1.1 by Investigator assessment | 3 years | PFS per RECISTv1.1, by Investigator assessment, comparing INBRX-109 and placebo. |
| Secondary | Quality of life assessed by EORTC questionnaire for cancer patients (QLQ-C30) comparing INBRX-109 and placebo | 3 years | Quality of life will be determined. |
| Secondary | DCR per RECISTv1.1 by real-time IRR | 3 years | measured by DCR per RECISTv1.1, assessed by central real-time IRR, comparing INBRX-109 and placebo |
| Secondary | DOR per RECISTv1.1 by real-time IRR | 3 years | evaluate duration of response (DOR) per RECISTv1.1, assessed by central real-time IRR, comparing INBRX-109 and placebo |
| Secondary | To evaluate the safety and tolerability of INBRX-109 | 3 years | Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. |
| Secondary | Characterize the pharmacokinetics of INBRX-109. | 3 years | AUC0-inf, AUC0-last, AUC0-21d, Cmax, Ctrough, Tmax will be estimated using a standard non-compartmental method as the data allow. Other PK parameters (λz, t½, Vd, CL, and accumulation ratios RCmax, RCtrough) will be calculated if data permit. |
| Secondary | Immunogenicity of INBRX-109 | 3 years | Frequency of anti-drug antibodies against INBRX-109 will be determined. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04950075
GET https://conductscience.org/api/trials/v1/NCT04950075/registered